Ajanta Pharma Ltd (AJANTPHARM) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Ajanta Pharma reported strong Q1 FY26 results with 14% revenue growth and resilient margins.
- The company demonstrated strong financial health with ROCE at 33% and ROE at 26%.
- Cash conversion was robust at 80%, with free cash flow to PAT conversion at 82%.
- Branded generics in Asia and Africa contributed 41% to total revenue.
- US Generics performed exceptionally well, achieving 36% growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.